Teleflex Incorporated announced that the ARROW UltraQuik peripheral nerve block (PNB) needles have received 510(k) clearance from the U.S. Food and Drug Administration (FDA). ARROW UltraQuik peripheral nerve block needles are designed to help increase overall block success for clinicians who use ultrasound-guidance when performing single-injection PNBs. UltraQuik needles maintain many of the same clinician-inspired features of the ARROW(R) StimuQuik(R) ECHO needles, including five grooved rings at the distal tip of the needle to help clinicians identify the needle tip under ultrasound.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
230.3 USD | +0.44% | +4.41% | -7.64% |
16/07 | Truist Raises Price Target on Teleflex to $240 From $235, Maintains Hold Rating | MT |
09/07 | Truist Securities Adjusts Price Target on Teleflex to $235 From $219, Maintains Hold Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-7.64% | 10.85B | |
-4.90% | 182B | |
-1.36% | 104B | |
-7.64% | 45.58B | |
+9.30% | 46.44B | |
+9.63% | 44.34B | |
+13.63% | 29.44B | |
+20.29% | 26.8B | |
-7.12% | 23.82B | |
+4.03% | 22.61B |
- Stock Market
- Equities
- TFX Stock
- News Teleflex Incorporated
- Teleflex Incorporated's ARROW(R) UltraQuik(TM) Peripheral Nerve Block Needles Receive FDA 510(k) Clearance